Thumbnail Image
Publication

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Sartor, O
; 
Coleman, R
; 
Nilsson, S
; 
Heinrich, D
; 
Helle, S
; 
O'Sullivan, J
; 
Fosså, S
; 
Chodacki, A
; 
Wiechno, P
; 
Logue, John P
... show 10 more
Citations
Altmetric:
Abstract
Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases.
Authors
Sartor, O
Coleman, R
Nilsson, S
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Widmark, A
Johannessen, D
Hoskin, P
James, N
Solberg, A
Syndikus, I
Vogelzang, N
O'Bryan-Tear, C
Shan, M
Bruland, O
Parker, C
Affiliation
Tulane Cancer Center, New Orleans, LA, USA.
Description
Date
2014-06
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. 2014, 15 (7):738-46 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/322637
Embedded videos